AR050537A1 - Produccion de proteina de fusion tnfr-ig - Google Patents

Produccion de proteina de fusion tnfr-ig

Info

Publication number
AR050537A1
AR050537A1 ARP050103596A ARP050103596A AR050537A1 AR 050537 A1 AR050537 A1 AR 050537A1 AR P050103596 A ARP050103596 A AR P050103596A AR P050103596 A ARP050103596 A AR P050103596A AR 050537 A1 AR050537 A1 AR 050537A1
Authority
AR
Argentina
Prior art keywords
culture
accumulated
tnfr
glutamine
conditions
Prior art date
Application number
ARP050103596A
Other languages
English (en)
Spanish (es)
Original Assignee
Wyeth Res Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35500648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050537(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Res Ireland Ltd filed Critical Wyeth Res Ireland Ltd
Publication of AR050537A1 publication Critical patent/AR050537A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95Protein-free medium and culture conditions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP050103596A 2004-08-27 2005-08-26 Produccion de proteina de fusion tnfr-ig AR050537A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60537904P 2004-08-27 2004-08-27

Publications (1)

Publication Number Publication Date
AR050537A1 true AR050537A1 (es) 2006-11-01

Family

ID=35500648

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103596A AR050537A1 (es) 2004-08-27 2005-08-26 Produccion de proteina de fusion tnfr-ig
ARP120104234A AR088824A2 (es) 2004-08-27 2012-11-09 Metodo para la produccion de tnfr-ig (receptor de factor de necrosis tumoral-inmunoglobulina)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP120104234A AR088824A2 (es) 2004-08-27 2012-11-09 Metodo para la produccion de tnfr-ig (receptor de factor de necrosis tumoral-inmunoglobulina)

Country Status (37)

Country Link
US (1) US7300773B2 (enExample)
EP (2) EP1781802B1 (enExample)
JP (3) JP2008511330A (enExample)
KR (1) KR100988451B1 (enExample)
CN (2) CN102876761A (enExample)
AR (2) AR050537A1 (enExample)
AT (2) ATE461285T1 (enExample)
AU (1) AU2005280036B2 (enExample)
BR (1) BRPI0514694B8 (enExample)
CA (1) CA2578138C (enExample)
CL (1) CL2017000577A1 (enExample)
CR (2) CR8998A (enExample)
CY (2) CY1109721T1 (enExample)
DE (2) DE602005020076D1 (enExample)
DK (2) DK1992697T3 (enExample)
EC (1) ECSP077354A (enExample)
EG (1) EG26922A (enExample)
ES (2) ES2335518T3 (enExample)
GT (2) GT200500234A (enExample)
HN (1) HN2005000485A (enExample)
HR (2) HRP20100011T1 (enExample)
IL (1) IL181588A (enExample)
MX (1) MX2007002381A (enExample)
MY (1) MY137803A (enExample)
NO (1) NO344785B1 (enExample)
NZ (1) NZ579208A (enExample)
PE (2) PE20100448A1 (enExample)
PL (2) PL1992697T3 (enExample)
PT (2) PT1781802E (enExample)
RS (2) RS51255B (enExample)
RU (1) RU2458988C2 (enExample)
SI (2) SI1992697T1 (enExample)
SV (1) SV2006002211A (enExample)
TW (1) TWI364458B (enExample)
UA (1) UA89383C2 (enExample)
WO (1) WO2006026447A2 (enExample)
ZA (1) ZA200701672B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
ES2668212T3 (es) * 2006-07-13 2018-05-17 Wyeth Llc Producción de factor de coagulación IX con patrón de glucosilación mejorado
JP5401319B2 (ja) * 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
ES2538986T3 (es) * 2006-11-08 2015-06-25 Wyeth Llc Medios diseñados racionalmente para un cultivo celular
PL2115126T3 (pl) * 2007-03-02 2015-08-31 Wyeth Llc Zastosowanie miedzi i glutaminianu w hodowli komórkowej do wytwarzania polipeptydów
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
CN105567627B (zh) 2007-04-26 2020-09-29 中外制药株式会社 使用含高浓度氨基酸的培养基的细胞培养方法
HUE027035T2 (hu) * 2008-04-17 2016-08-29 Wyeth Llc Eljárások csont morfogenetikus fehérjék termelésének fokozására
JP2011516086A (ja) * 2008-04-18 2011-05-26 上海中信国健薬業股▲ふん▼有限公司 濃縮培養液及びその使用方法
EP2331700A2 (en) 2008-08-08 2011-06-15 Biogen Idec MA Inc. Nutrient monitoring and feedback control for increased bioproduct production
FI2464725T4 (fi) 2009-08-11 2025-03-21 Hoffmann La Roche Proteiinien tuotanto glutamiinittomassa soluviljelyn elatusaineessa
CN102770458A (zh) * 2009-12-02 2012-11-07 阿塞勒隆制药公司 用于增加Fc融合蛋白的血清半寿期的组合物和方法
RU2563353C2 (ru) 2010-04-26 2015-09-20 Новартис Аг Улучшенная среда для культивирования клеток
LT3330370T (lt) 2010-04-26 2021-06-10 Novartis Ag Cho ląstelių auginimo būdas
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
US20130331554A1 (en) 2010-11-15 2013-12-12 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
KR101591671B1 (ko) 2011-04-29 2016-02-04 바이오콘 리서치 리미티드 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
AR088379A1 (es) 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con iones metalicos
CA2852021C (en) 2011-10-21 2018-08-28 Pfizer Inc. Addition of iron to improve cell culture
JP2015509714A (ja) * 2012-02-22 2015-04-02 エヌヴィーアイピー プロプライエタリー リミテッド 腫瘍壊死因子レセプター融合タンパク質及び前記タンパク質を使用する方法
JP6271536B2 (ja) 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
MX362922B (es) 2013-03-26 2019-02-25 Coherus Biosciences Inc Método de producción de proteínas.
KR101439195B1 (ko) 2013-04-18 2014-09-12 동아대학교 산학협력단 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
ES2678945T3 (es) * 2013-10-11 2018-08-21 Regeneron Pharmaceuticals, Inc. Cultivos celulares optimizados metabólicamente
EP3683316A1 (en) 2014-01-30 2020-07-22 Coherus Biosciences, Inc. Perfusion media
KR102567586B1 (ko) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
LT3227454T (lt) * 2014-12-01 2020-07-27 Amgen Inc. Glikoproteino glikano sudedamosios dalies kiekio keitimo procedūra
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105777897A (zh) * 2015-03-20 2016-07-20 广东东阳光药业有限公司 一种cho细胞收获液的前处理方法
CN114807010B (zh) * 2015-04-01 2024-11-29 勃林格殷格翰国际公司 细胞培养基
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
SG11201903521XA (en) 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
CN110484487A (zh) * 2019-08-21 2019-11-22 安徽欣乐生物技术有限公司 一种适用于cho细胞培养用无蛋白培养基及其培养方法
JP2024503239A (ja) 2020-12-22 2024-01-25 アムジェン インコーポレイテッド 細胞培養法
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
CN114480492B (zh) * 2022-01-28 2023-04-21 景泽生物医药(合肥)股份有限公司 一种重组人抗体融合蛋白的制备方法
CN119510778A (zh) * 2024-12-31 2025-02-25 北京同立海源生物科技有限公司 一种高稳定性的pdgf-bb活性检测方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990003430A1 (en) * 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
WO1991005058A1 (en) * 1989-10-05 1991-04-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) * 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
GB9118664D0 (en) * 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性IgE受容体モノクローナル抗体に係るアミノ酸配列をコードするDNA断片
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
WO2002088307A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
ATE420114T1 (de) 2001-04-30 2009-01-15 Lilly Co Eli Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;
EP1404813A4 (en) 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
IL163525A0 (en) 2002-02-21 2005-12-18 Wyeth Corp A follistatin domain containing protein
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法

Also Published As

Publication number Publication date
NO344785B1 (no) 2020-04-27
CY1110092T1 (el) 2015-01-14
NO20071570L (no) 2007-05-23
KR100988451B1 (ko) 2010-10-18
MX2007002381A (es) 2007-06-15
CN101061231A (zh) 2007-10-24
WO2006026447A2 (en) 2006-03-09
JP2016056214A (ja) 2016-04-21
CL2017000577A1 (es) 2017-12-01
GT200500234A (es) 2006-10-10
HRP20100271T1 (hr) 2010-06-30
TWI364458B (en) 2012-05-21
ECSP077354A (es) 2007-05-30
ATE461285T1 (de) 2010-04-15
ES2335518T3 (es) 2010-03-29
KR20070069140A (ko) 2007-07-02
CR8998A (es) 2007-11-23
PT1992697E (pt) 2010-04-21
EP1992697B1 (en) 2010-03-17
PL1781802T3 (pl) 2010-03-31
BRPI0514694B8 (pt) 2021-05-25
SI1781802T1 (sl) 2010-01-29
PE20060815A1 (es) 2006-09-14
MY137803A (en) 2009-03-31
PL1992697T3 (pl) 2010-08-31
PE20100448A1 (es) 2010-06-22
BRPI0514694A (pt) 2008-06-17
HN2005000485A (es) 2009-06-09
DK1992697T3 (da) 2010-05-17
CA2578138A1 (en) 2006-03-09
AU2005280036A1 (en) 2006-03-09
DE602005020076D1 (de) 2010-04-29
CR20120560A (es) 2012-12-04
AU2005280036B2 (en) 2011-11-03
HRP20100011T1 (hr) 2010-02-28
IL181588A0 (en) 2007-07-04
EP1781802A2 (en) 2007-05-09
JP2008511330A (ja) 2008-04-17
US7300773B2 (en) 2007-11-27
ZA200701672B (en) 2012-04-24
WO2006026447A3 (en) 2006-04-20
US20060121569A1 (en) 2006-06-08
RS51072B (sr) 2010-10-31
JP5921910B2 (ja) 2016-05-24
CA2578138C (en) 2010-10-05
NZ579208A (en) 2012-01-12
GT200500233A (es) 2006-03-09
EG26922A (en) 2014-12-25
ES2341390T3 (es) 2010-06-18
UA89383C2 (ru) 2010-01-25
EP1781802B1 (en) 2009-10-21
CN101061231B (zh) 2012-09-26
EP1992697A1 (en) 2008-11-19
SI1992697T1 (sl) 2010-07-30
SV2006002211A (es) 2006-10-04
BRPI0514694B1 (pt) 2019-04-24
RS51255B (sr) 2010-12-31
RU2007108717A (ru) 2008-10-10
CN102876761A (zh) 2013-01-16
DK1781802T3 (da) 2010-01-25
JP2012095672A (ja) 2012-05-24
TW200619388A (en) 2006-06-16
DE602005017285D1 (enExample) 2009-12-03
WO2006026447A9 (en) 2006-06-01
IL181588A (en) 2010-12-30
HK1121497A1 (en) 2009-04-24
AR088824A2 (es) 2014-07-10
RU2458988C2 (ru) 2012-08-20
CY1109721T1 (el) 2014-08-13
ATE446376T1 (de) 2009-11-15
PT1781802E (pt) 2010-01-04
HK1099941A1 (en) 2007-08-31

Similar Documents

Publication Publication Date Title
AR050537A1 (es) Produccion de proteina de fusion tnfr-ig
AR050471A1 (es) Produccion de anticuerpos anti abeta -amiloide
AR051017A1 (es) Produccion de polipeptidos
CL2008001156A1 (es) Metodo para producir una proteina de fusion tnfr en un cultivo celular que comprende cultivar celulas de mamifero que contienen un gen que codifica la proteina de fusion en un medio de cultivo de celulas que comprende un compuesto anti-envejecimiento.
ECSP088395A (es) Método de producción proteica utilizando compuestos anti-senescencia
WO2012079086A3 (en) Mesenchymal stem cells (msc) expansion methods and materials
WO2007084364A3 (en) Improved il-12 for expression in mammalian cells
MX2011008373A (es) Procedimiento para la criopreservacion de celulas, construcciones celulares artificiales o ensamblajes de tejidos complejos tridimensionales.
DE69902810D1 (de) Verfahren zur herstellung einer festpolymerelektrolytmembran
EP2588594A4 (en) PROCESS FOR CULTIVATING UNDIFFERENCED CELLS USING DELAYED RELATED COMPOSITION COMPOSITIONS
UA92157C2 (ru) Способ продуцирования гормона роста
EP4455166A3 (en) Method for producing cd3-positive cell
ATE324434T1 (de) Verfahren zur herstellung künstlicher pflanzenchromosomen
WO2004091033A3 (fr) Composition reticulable pour electrolyte de batterie
CO6390009A2 (es) Reactor electrobioquimico
JP2020065503A5 (enExample)
BRPI0814082A2 (pt) Cultura incluindo um meio de expansão e uma composição de citocinas, método para a expansão de células-tronco, células-tronco e uso de células
BRPI0418641A (pt) organização similar a tecido de células e construtos similares a tecidos macroscópicos, gerados por cultura de macromassa de células, e método de cultura de macromassa
BR112021020501A2 (pt) Meio de cultura celular para células eucarióticas
MX2021011146A (es) Andamio biodegradable para el crecimiento de cabello y metodos de uso para el mismo.
EP3467112A3 (en) Methods for transfecting nucleic acids into live cells
ATE309344T1 (de) Verfahren zur aufbereitung von biomasse zur herstellung von plasmid dna haltigem zelllysat
MX2007005928A (es) Metodos para la produccion de celulas de mamiferos.
EP1885844A4 (en) Preparation and use of basement membrane particles
BRPI0415446A (pt) recombinação mediada por flp

Legal Events

Date Code Title Description
FC Refusal